Huge study questions HRT's role in heart health

Sibbald, Barbara
May 2000
CMAJ: Canadian Medical Association Journal;5/30/2000, Vol. 162 Issue 11, p1603
Academic Journal
Reports the results of a study done by the United States National Institute of Health (NIH) which found that women taking estrogen had more heart attacks, strokes and blood clots than women taking placebos. The number of women in the United States who are taking hormone replacement therapy (HRT) for its heart-protecting qualities; The effect of their health habits on the incidence of heart disease; Findings of a study in the August 1998 issue of the `Journal of the American Medical Association.'


Related Articles

  • Officials Halt NSAID Prevention Trials. Hampton, Tracy // JAMA: Journal of the American Medical Association;2/9/2005, Vol. 293 Issue 6, p664 

    Reports that two government sponsored medical studies involving the use of NSAIDs have been halted after both showed that there was a greater risk of stroke and heart attacks in participants on the drugs; Use of celecoxib in a colorectal cancer study and an Alzheimer's Disease trial which...

  • A PAINKILLER CRUMBLES.  // njbiz;10/4/2004, Vol. 17 Issue 40, p2 

    Reports on the decision of drug maker Merck to stop selling the painkiller Vioxx amid claims that patients taking it were exposed to a heightened risk of heart attacks and strokes. Annual sales of Vioxx; Reaction of investors to the decision; Speculation on the reason for the decision to stop...

  • PPIs may cause heart attack in clopidogrel recipients.  // Reactions Weekly;5/16/2009, Issue 1252, p1 

    The article reports on the conclusion of the Clopidogrel Outcomes Study that common heartburn medication proton pump inhibitors (PPI) may cause heart attacks and stroke in patients receiving clopidogrel treatment. PPI increased the risk of heart attacks and stroke due to decreased antiplatelet...

  • Varespladib trial terminated, increased MI risk.  // Reactions Weekly;1/18/2014, Issue 1484, p1 

    The article discusses the termination of the VISTA-16 clinical trial of varespladib in patients with acute coronary syndrome as the drug found to be associated with increased risk of myocardial infarction (MI) as recommended by the independent data and safety monitoring board in the U.S.

  • When it comes to BP, low may not be low enough. Moore, Amy Slugg // RN;Dec98, Vol. 61 Issue 12, p18 

    Cites a study which found that patients have the least risk of heart attack or stroke and dying from either, when their diastolic blood pressure is below the recommended level. Finding from the Hypertension Optimal Treatment study; Evaluation of the benefits of adding low-dose aspirin to a...

  • Lose your temper--and your life?  // Consumer Reports on Health;Aug95, Vol. 7 Issue 8, p88 

    Reports on a study of 100 men which found a positive relationship between the anger scores from a psychological test taken in their twenties and the likelihood of having a heart attack or a stroke during midlife.

  • More Questions About COX-2 Arthritis Drugs.  // Tufts University Health & Nutrition Letter;Jan2005, Vol. 22 Issue 11, p2 

    Reports on the clinical trials conducted to identify the role of arthritis medication COX-2 inhibitors in increasing the risk of heart attacks and strokes. Results of the clinical trial conducted by researcher Garret A. Fitzgerald on Bextra, a COX-2 painkiller from Pfizer; Position of Pfizer...

  • Aspirin prevents stroke, but not MI, in women.  // BMJ: British Medical Journal (International Edition);7/23/2005, Vol. 331 Issue 7510, p168 

    Presents the results of a study on the impact of aspirin on the risk for cardiovascular disease in women. Details of the study, which focused on middle-aged women with no history of cardiovascular disease; Details of the study's outcome; Report that aspirin reduces the risk of stroke and...

  • Rosiglitazone � Continued Uncertainty about Safety. Drazen, Jeffrey M.; Morrissey, Stephen; Curfman, Gregory D. // New England Journal of Medicine;7/5/2007, Vol. 357 Issue 1, p63 

    This editorial looks at the continued uncertainty about the safety of the drug rosiglitazone, which is used in the treatment of diabetes. The inconclusive results from an interim report from the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) trial...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics